$CNTB News

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Target of $8

Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $7

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation

Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026

Cantor Fitzgerald Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $4

Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Proceeds With Phase 2 Enrollment For Rademikibart Following Interim Efficacy Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate

BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript